Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence

Conditions

HIV/AIDS

What is the purpose of this trial?

The purpose of this study is to develop ways to examine how HIV stays in your body after someone starts medication assisted therapy (MAT) (e.g. buprenorphine/naloxone, buprenorphine, methadone or extended-release naltrexone), for the treatment of opioid use disorder, and to see how different types of MAT changes how HIV in the body.

The researchers will follow all participants and schedule regular interviews and blood draws to gather information. This will enable them to look at the presence of specific factors associated with HIV and treatment for opioid use disorder over time.  The study will last for 3 months.

  • Trial with
    National Institute on Drug Abuse (NIDA)
  • Start Date
    10/21/2018
  • End Date
    04/29/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Breanne Biondi

  • Last Updated
    02/04/2019
  • Study HIC
    #2000023013